Experimental models further indicate that dysregulation of SphK2 directly induces NAFLD and participates in the carcinogenic process associated with non-alcoholic steatohepatitis (NASH) through S1P-mediated epigenetic reprogramming (36). This evidence concerns the gene SPHK2 and metabolic dysfunction-associated steatotic liver disease.